دورية أكاديمية
أعرض في EDS

AAV-Mediated CAG-Targeting Selectively Reduces Polyglutamine-Expanded Protein and Attenuates Disease Phenotypes in a Spinocerebellar Ataxia Mouse Model.

التفاصيل البيبلوغرافية
العنوان: AAV-Mediated CAG-Targeting Selectively Reduces Polyglutamine-Expanded Protein and Attenuates Disease Phenotypes in a Spinocerebellar Ataxia Mouse Model.
المؤلفون: Niewiadomska-Cimicka A; Institute of Genetics and Molecular and Cellular Biology, INSERM U1258, CNRS UMR7104, University of Strasbourg, 67404 Illkirch, France., Fievet L; Institute of Genetics and Molecular and Cellular Biology, INSERM U1258, CNRS UMR7104, University of Strasbourg, 67404 Illkirch, France., Surdyka M; Department of Molecular Neurobiology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland., Jesion E; Department of Molecular Neurobiology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland., Keime C; Institute of Genetics and Molecular and Cellular Biology, INSERM U1258, CNRS UMR7104, University of Strasbourg, 67404 Illkirch, France., Singer E; Centre for Rare Diseases (ZSE), University of Tuebingen, 72076 Tuebingen, Germany.; Institute of Medical Genetics and Applied Genomics, University of Tuebingen, 72076 Tuebingen, Germany.; Department of Human Genetics, Medical Faculty, Ruhr University Bochum, 44801 Bochum, Germany., Eisenmann A; Institute of Genetics and Molecular and Cellular Biology, INSERM U1258, CNRS UMR7104, University of Strasbourg, 67404 Illkirch, France., Kalinowska-Poska Z; Department of Molecular Neurobiology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland., Nguyen HHP; Department of Human Genetics, Medical Faculty, Ruhr University Bochum, 44801 Bochum, Germany., Fiszer A; Department of Medical Biotechnology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland., Figiel M; Department of Molecular Neurobiology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland., Trottier Y; Institute of Genetics and Molecular and Cellular Biology, INSERM U1258, CNRS UMR7104, University of Strasbourg, 67404 Illkirch, France.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Apr 15; Vol. 25 (8). Date of Electronic Publication: 2024 Apr 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Spinocerebellar Ataxias*/genetics , Spinocerebellar Ataxias*/therapy , Spinocerebellar Ataxias*/metabolism , Peptides*/genetics , Disease Models, Animal* , Dependovirus*/genetics , Ataxin-7*/genetics , Ataxin-7*/metabolism , Trinucleotide Repeat Expansion*/genetics , RNA, Small Interfering*/genetics , Phenotype*, Animals ; Mice ; Genetic Vectors/genetics ; Genetic Vectors/administration & dosage ; Purkinje Cells/metabolism ; Purkinje Cells/pathology ; Mice, Transgenic ; Cerebellum/metabolism ; Cerebellum/pathology ; Humans ; Genetic Therapy/methods ; Alleles
مستخلص: Polyglutamine (polyQ)-encoding CAG repeat expansions represent a common disease-causing mutation responsible for several dominant spinocerebellar ataxias (SCAs). PolyQ-expanded SCA proteins are toxic for cerebellar neurons, with Purkinje cells (PCs) being the most vulnerable. RNA interference (RNAi) reagents targeting transcripts with expanded CAG reduce the level of various mutant SCA proteins in an allele-selective manner in vitro and represent promising universal tools for treating multiple CAG/polyQ SCAs. However, it remains unclear whether the therapeutic targeting of CAG expansion can be achieved in vivo and if it can ameliorate cerebellar functions. Here, using a mouse model of SCA7 expressing a mutant Atxn7 allele with 140 CAGs, we examined the efficacy of short hairpin RNAs (shRNAs) targeting CAG repeats expressed from PHP.eB adeno-associated virus vectors (AAVs), which were introduced into the brain via intravascular injection. We demonstrated that shRNAs carrying various mismatches with the CAG target sequence reduced the level of polyQ-expanded ATXN7 in the cerebellum, albeit with varying degrees of allele selectivity and safety profile. An shRNA named A4 potently reduced the level of polyQ-expanded ATXN7, with no effect on normal ATXN7 levels and no adverse side effects. Furthermore, A4 shRNA treatment improved a range of motor and behavioral parameters 23 weeks after AAV injection and attenuated the disease burden of PCs by preventing the downregulation of several PC-type-specific genes. Our results show the feasibility of the selective targeting of CAG expansion in the cerebellum using a blood-brain barrier-permeable vector to attenuate the disease phenotype in an SCA mouse model. Our study represents a significant advancement in developing CAG-targeting strategies as a potential therapy for SCA7 and possibly other CAG/polyQ SCAs.
References: Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700)
Cell. 2012 Aug 31;150(5):895-908. (PMID: 22939619)
Genes Dev. 2014 Feb 1;28(3):259-72. (PMID: 24493646)
Cell Rep. 2018 Jul 3;24(1):95-106.e9. (PMID: 29972794)
Mol Ther Nucleic Acids. 2020 Mar 6;19:562-571. (PMID: 31927329)
Genes (Basel). 2016 Dec 17;7(12):. (PMID: 27999335)
Genome Biol. 2010;11(10):R106. (PMID: 20979621)
Hum Mol Genet. 2019 Mar 15;28(6):912-927. (PMID: 30445451)
Front Neural Circuits. 2021 Jun 14;15:661899. (PMID: 34194302)
Adv Exp Med Biol. 2019;1185:109-112. (PMID: 31884597)
Front Mol Neurosci. 2022 Sep 13;15:947490. (PMID: 36176957)
Biologics. 2022 Sep 30;16:141-160. (PMID: 36213816)
Mol Brain. 2010 Aug 02;3:23. (PMID: 20678225)
Ann Clin Transl Neurol. 2018 Jan 22;5(3):297-314. (PMID: 29560375)
PLoS One. 2024 Jan 16;19(1):e0296790. (PMID: 38227598)
J Neurol. 2001 Oct;248(10):911-4. (PMID: 11697534)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Nat Rev Dis Primers. 2019 Apr 11;5(1):24. (PMID: 30975995)
PLoS One. 2017 Feb 9;12(2):e0171127. (PMID: 28182673)
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1488-93. (PMID: 9037080)
Biochem Biophys Res Commun. 2008 Mar 21;367(4):787-92. (PMID: 18201550)
J Neurosci. 2021 Jun 2;41(22):4910-4936. (PMID: 33888607)
Eur J Hum Genet. 2004 Jan;12(1):2-15. (PMID: 14571264)
Dev Biol. 2014 Oct 1;394(1):39-53. (PMID: 25128586)
Cell Rep. 2017 Apr 18;19(3):532-544. (PMID: 28423317)
Hum Mol Genet. 1999 Dec;8(13):2473-8. (PMID: 10556295)
Elife. 2021 May 13;10:. (PMID: 33983118)
Nat Neurosci. 2017 Aug;20(8):1172-1179. (PMID: 28671695)
Nucleic Acids Res. 2013 Dec;41(22):10426-37. (PMID: 24038471)
Brain. 2020 Feb 1;143(2):407-429. (PMID: 31738395)
Acta Biochim Pol. 2016;63(4):759-764. (PMID: 27770571)
Prog Neurobiol. 2013 May;104:38-66. (PMID: 23438480)
Neurotherapeutics. 2019 Apr;16(2):263-286. (PMID: 30607747)
J Vis Exp. 2015 Feb 06;(96):e52434. (PMID: 25742564)
Bioinformatics. 2020 Apr 15;36(8):2628-2629. (PMID: 31882993)
Hum Mol Genet. 1998 Feb;7(2):177-86. (PMID: 9425224)
Chem Rec. 2008;8(6):378-85. (PMID: 19107867)
Nat Methods. 2012 Mar 04;9(4):357-9. (PMID: 22388286)
Neuron. 2003 Feb 6;37(3):383-401. (PMID: 12575948)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Cerebellum. 2013 Jun;12(3):390-5. (PMID: 23100044)
Cell Mol Life Sci. 2021 Feb;78(4):1577-1596. (PMID: 32696070)
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12407-E12416. (PMID: 30530649)
Nucleic Acids Res. 2012 Dec;40(22):11270-80. (PMID: 23042244)
PLoS One. 2012;7(11):e50705. (PMID: 23226359)
Mol Ther Nucleic Acids. 2019 Sep 6;17:601-614. (PMID: 31394429)
Brain Commun. 2021 May 17;3(2):fcab105. (PMID: 34131644)
Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):6023-6034. (PMID: 32132200)
Mol Ther Nucleic Acids. 2022 May 05;28:702-715. (PMID: 35664700)
Hum Mol Genet. 1998 Feb;7(2):165-70. (PMID: 9425222)
Nat Rev Neurosci. 2017 Oct;18(10):613-626. (PMID: 28855740)
معلومات مُعتمدة: ERA-NET-E-RARE-3/III/TreatPolyQ/08/2018 European Research Projects on Rare Diseases; ANR-17-RAR3-0008-04_ACT Agence Nationale de la Recherche; 688790 National Ataxia Foundation; 2015/17/D/NZ5/03443 Polish National Science Centre
فهرسة مساهمة: Keywords: CAG repeat expansion; CAG-targeting therapy; Spinocerebellar ataxia; adeno-associated virus; allele selectivity; short hairpin RNA
المشرفين على المادة: 0 (Peptides)
26700-71-0 (polyglutamine)
0 (Ataxin-7)
0 (RNA, Small Interfering)
0 (Atxn7 protein, mouse)
تواريخ الأحداث: Date Created: 20240427 Date Completed: 20240427 Latest Revision: 20240521
رمز التحديث: 20240521
مُعرف محوري في PubMed: PMC11050704
DOI: 10.3390/ijms25084354
PMID: 38673939
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25084354